Income Statement (Annual)
LJPC / La Jolla Pharmaceutical Co. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Adminstrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000 except per share units.
|Revenue From Contract With Customer Including Assessed Tax||-||-||-||-||-||-||-||-|
|Costs And Expenses|
|Cost Of Goods And Services Sold||-||-||-||-||-||-||-||-|
|Research And Development Expense||13||177||1,353||4,362||9,944||29,092||62,288||84,575|
|General And Administrative Expense||3,915||2,097||9,386||13,577||11,396||13,934||16,700||30,852|
|Costs And Expenses||3,928||2,274||10,739||17,939||21,340||43,026||78,988||115,427|
|Operating Income Loss||-3,928||-2,274||-10,739||-17,939||-21,340||-41,969||-78,372||-115,427|
|Interest Income Expense Net||-||-||-||-||-||-||-||-|
|Net Income Loss||-3,760||-11,548||-7,737||-17,935||-21,313||-41,912||-78,185||-114,803|
|Earnings Per Share Basic And Diluted||-0||-0||-0||-0||-0||-0||-0||-0|
|Weighted Average Number Of Share Outstanding Basic And Diluted||-||369||10,196||454,337||10,667||15,651||17,228||21,215|
Peers - Biological Products, Except Diagnostic Substances (Biotech) (2836)
APEN / Apollo Endosurgery Inc.
ARIA / ARIAD Pharmaceuticals, Inc.
AVIR / Aviragen Therapeutics, Inc.
AVXS / AveXis, Inc.
BOTA / Biota Pharmaceuticals, Inc.
CASI / CASI Pharmaceuticals, Inc.
CYTR / CytRx Corp.
EIGR / Eiger BioPharmaceuticals, Inc.
FENC / Fennec Pharmaceuticals Inc.
Related News Stories
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (298-8)
Biotechnology stocks have a reputation for being some of the most speculative, most volatile stocks out there. Investors and would-be investors have to stay alert to avoid getting burned. One encouraging sign in any company is when insiders put their money where their mouth is and buy shares. Lately, some insiders at biotech companies have been doing just that, sometimes taking advantage of share price moves (not to mention buy windows opening up) in the wake of the release of quarterly reports. (24-12)
La Jolla Pharmaceutical Co (NASDAQ:LJPC) Q2 2018 Earnings Conference Call August 8, 2018 4:30 PM ET
Galectin Therapeutics (NASDAQ:GALT) announced on June 27th its patent for the method and treatment of Idiopathic Pulmonary Fibrosis (NYSEARCA:IPF). The significance of this patent was initially received as extremely positive by the market, but recent structural pressures like the option exercise of a key departing officer continued to weigh on the price. Based on the recent Form 4 Filings, the selling pressure has abated because the officers have simply run out of options to sell. (24-2)
Biotech stocks represent a peculiar conundrum. On one hand, they are scientifically the most exciting investment sector. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. But the industry is heavily marked with failures and agonizing disappointments. (7-1)
as of ET